Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ: ANIK) announced participation in three upcoming virtual investor conferences this May. Dr. Cheryl Blanchard, CEO, and Michael Levitz, CFO, will present at the following events: the 16th Annual Canaccord Genuity Musculoskeletal Conference on May 20, starting at 9:00 a.m. ET, the UBS Global Healthcare Virtual Conference on May 25, starting at 8:00 a.m. ET, and Oppenheimer’s MedTech Summit with a pre-recorded session on May 26. All presentations will be accessible via Anika's Investor Relations website.
Anika Therapeutics (NASDAQ: ANIK) plans to release its first quarter 2021 financial results on May 6, 2021, after market close. Following the release, the company will hold an investor conference call at 5:00 p.m. ET to discuss financials and business updates. Interested parties can access the call by phone or through a live audio webcast available on Anika's Investor Relations webpage. Anika specializes in joint preservation and minimally invasive orthopedic solutions, focusing on areas like osteoarthritis pain management and regenerative therapies.
Anika Therapeutics (NASDAQ: ANIK) has announced that Dr. Cheryl Blanchard, President and CEO, and Michael Levitz, CFO, will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 3:45 p.m. ET. The event will be accessible via a live audio webcast on Anika's Investor Relations website, and an audio archive will be available post-event.
As a leader in joint preservation, Anika focuses on developing innovative orthopedic solutions for osteoarthritis and soft tissue repair, enhancing patient outcomes and active living.
Anika Therapeutics, a joint preservation company, will present at the Sidoti Spring Virtual Investor Conference on March 25, 2021, at 8:30 a.m. ET. The presentation will feature Dr. Cheryl Blanchard, President and CEO, alongside Michael Levitz, Executive Vice President and CFO. A live audio webcast will be available on Anika’s website, with an archive accessible later. Anika focuses on innovative orthopedic solutions, including osteoarthritis management and regenerative treatments.
Anika Therapeutics reported a 10% revenue increase in Q4 2020, totaling $32.7 million, and a 14% increase in full-year revenue to $130.5 million. The growth stemmed from joint preservation products following two acquisitions. However, the company faced a net loss of $15.7 million in Q4, attributed to goodwill impairment and acquisition-related expenses. Adjusted net income for the quarter was $1.7 million. For 2021, Anika is not providing detailed financial guidance due to ongoing COVID-19 uncertainties.
Anika Therapeutics (NASDAQ: ANIK) will release its fourth quarter and year-end 2020 financial results after market close on March 4, 2021. An investor conference call will follow at 5:00 p.m. ET to discuss these results and business highlights. Interested parties can access the call by dialing the provided numbers or via a live audio webcast available on Anika's Investor Relations page. The call will be archived for later access.
Anika Therapeutics reported a 7% increase in revenue year-over-year, totaling $31.7 million for Q3 2020, driven by its orthopedics segment and recent acquisitions. Despite this growth, the company experienced a net loss of $6.4 million, or $0.45 per diluted share, compared to net income of $9.2 million in the prior year. Cash and investments fell to $124.8 million due to significant acquisition costs. The firm is expanding its product portfolio and has resumed key clinical trials, aiming for sustainable growth despite challenges from COVID-19.
Anika Therapeutics (NASDAQ: ANIK) plans to release its third quarter 2020 financial results after market close on November 4, 2020. The company will also host an investor conference call on the same day at 5:00 PM ET to discuss the financial results and business highlights. Investors can participate by dialing in or accessing a live audio webcast via Anika's Investor Relations page.
Founded to advance orthopedic care, Anika specializes in joint preservation and minimally invasive products to aid in osteoarthritis pain management and other related areas.
Anika Therapeutics (NASDAQ: ANIK) announced on October 21, 2020, the FDA's 510(k) clearance of its WristMotion Total Arthroplasty System. This new system is designed for patients suffering from painful wrist joint conditions like rheumatoid arthritis and osteoarthritis. The device aims to preserve natural motion and anatomy, providing an alternative to traditional fusion methods. The approval also triggers a $5 million earnout payment due to the merger with Arthrosurface, expected in Q4 2020.
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced the retirement of Board Chair Dr. Joseph Bower after 27 years, effective at the 2021 Annual Meeting. His successor, Jeffery Thompson, has been a director since 2011 and has extensive experience in healthcare investment. The Board also welcomed new independent directors, John B. Henneman, III and Stephen Richard, enhancing their expertise in healthcare and risk management. The strategic appointments aim to bolster Anika’s growth strategy in orthopedic and regenerative solutions amidst a transformative phase for the company.